Orthopedic Uses of Teriparatide
- 542 Downloads
Teriparatide is a drug currently approved for treating patients with osteoporosis who are at high risk for future fracture. In the treatment of osteoporosis, teriparatide works as an anabolic agent stimulating bone formation throughout the skeleton by principally enhancing osteoblast-derived bone formation relative to osteoclast-derived bone resorption. The net effect is increased bone mass. For patients with a fracture, a similar process of increased bone formation is required transiently at the fracture site for repair. Teriparatide has been investigated in animal models and in patients as a potential agent to enhance fracture repair. In addition, evidence that teriparatide enhances chondrogenesis has generated interest in using the agent for articular cartilage repair. Research is currently underway to understand the effects teriparatide may have on mesenchymal stem cells, and on other effects that have been reported anecdotally in patients using the drug for osteoporosis care, including the healing of fracture nonunions and a decreased incidence of back pain. We review the current animal and human reports available on the uses of teriparatide in musculoskeletal diseases beyond osteoporosis.
KeywordsOrthopedic Teriparatide Fracture Osteoporosis Parathyroid hormone
Dr. Susan Bukata is on the speakers’ bureau and has done consulting for Eli Lilly; she has also done consulting for Amgen. Dr. J. Edward Puzas has done consulting for Eli Lilly and Novartis.
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
- 2.Kent GN, Loveridge N, Reeve J, et al.: Pharmacokinetics of synthetic human parathyroid hormone 1-34 in man measured by cytochemical bioassay and radioimmunoassay. Clin Sci (Lond) 1985, 68:171–177.Google Scholar
- 9.Andreassen TT, Willick GE, Morley P, Whitfield JF: Treatment with parathyroid hormone hPTH(1-34), hPTH (1-31), and monocyclic hPTH(1-31) enhances fracture strength and callus amount after withdrawal fracture strength and callus mechanical quality continue to increase. Calcif Tissue Int 2004, 74:351–356.CrossRefPubMedGoogle Scholar
- 17.•• Aspenberg P, Genant HK, Johansson T, et al.: Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res 2009 Jul 13 [Epub ahead of print]. This is the first placebo-controlled, double-blinded, randomized clinical trial investigating the use of teriparatide in humans to accelerate fracture healing. Although this study missed its primary end point with a dose greater than that which is used for osteoporosis, the trend for the dose currently used for osteoporosis suggests an effect. It is a fundamental study that all subsequent trials investigating biologic adjuvants for fracture healing will need to use as a comparator.Google Scholar
- 19.Bukata SV, Kaback L, Reynolds D, et al.: 1-34 PTH at physiologic doses in humans shows promise as a helpful adjuvant in difficult to heal fractures: an observational cohort of 145 patients. Presented at the 55th Annual Meeting of the Orthopaedic Research Society. Las Vegas, NV; February 25, 2009.Google Scholar
- 20.Peichl P, Krankenhaus Wien-Waehring E, Holzer G: Parathyroid hormone 1-84 accelerates fracture healing in pubic bones of elderly osteoporotic women. J Bone Miner Res 24(Suppl 1). Available at http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=9d4e83f0-6302-4327-8a9d-758dc56cc703. Accessed January 2010.
- 22.•• Chang JK, Chang LH, Hung SH, et al.: Parathyroid hormone 1-34 inhibits terminal differentiation of human articular chondrocytes and osteoarthritis progression in rats. Arthritis Rheum 2009, 60:3049–3060. This is the first animal study published looking at the potential role that teriparatide may play in treating early arthritis.Google Scholar
- 23.Sampson E, Ho CH, Awad H, et al.: Intermittent PTH(1-34) and PTHrP enhance hyaline cartilage regeneration in a rabbit full-thickness defect model. J Bone Miner Res 24(Suppl 1). Available at http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=71a2723d-3c7d-41b4-aea0-bc1b5abfc65d. Accessed January 2010.
- 24.Sampson E, O’Brien T, Awad H, et al.: PTH(1-34) protects against articular cartilage degeneration following meniscal/ligamentous injury in a mouse model of osteoarthritis. J Bone Miner Res 24(Suppl 1). Available at http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=b4d2b7bb-8741-485f-8792-853794628e8a. Accessed January 2010.